ArticleTransfusion medicine (Oxford, England)2005
Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates.
Article in Transfusion medicine (Oxford, England), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.Transfusion · 2022Article
- Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components.Transfusion · 2022Article
- Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies.Pathogens (Basel, Switzerland) · 2022Article
- Impact of COVID-19 and lockdown regarding blood transfusion.Transfusion · 2021Article
- Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.Vox sanguinis · 2021Article
- Maintaining plasma quality and safety in the state of ongoing epidemic - The role of pathogen reduction.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
- Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.Vox sanguinis · 2021Article
- Convalescent Plasma Therapy for COVID-19: State of the Art.Clinical microbiology reviews · 2020Review
- Hand disinfection in the combat against COVID-19.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.Transfusion · 2020Review
- Is SARS-CoV-2 transfusion transmitted?Transfusion · 2020Article
- Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates.Transfusion medicine (Oxford, England) · 2019Article
- Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.Blood transfusion = Trasfusione del sangue · 2019Article
- How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?Transfusion · 2019Article
- Article
- Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light.Transfusion · 2018Article
- In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.Blood transfusion = Trasfusione del sangue · 2015Article
- Can biowarfare agents be defeated with light?Virulence · 2013Review
- [Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP].Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel human coronavirus causing severe acute respiratory syndrome (SARS) emerged in epidemic form in early 2003 in China and spread worldwide in a few months. Every newly emerging human pathogen is of concern for the safety of the blood supply during and after an epidemic crisis. For this purpose, we have evaluated the inactivation of SARS-coronavirus (CoV) in platelet concentrates using an approved pathogen inactivation device, the INTERCEPT Blood System. Apheresis platelet concentrates (APCs) were inoculated with approximately 10(6) pfu mL(-1) of either Urbani or HSR1 isolates of SARS-CoV. The inoculated units were mixed with 150 microm amotosalen and illuminated with 3 J cm(-2) UV-A light. The viral titres were determined by plaque formation in Vero E6 cells. Mixing SARS-CoV with APC in the absence of any treatment decreased viral infectivity by approximately 0.5-1 log10. Following photochemical treatment, SARS-CoV was consistently inactivated to the limit of detection in seven independent APC units. No infectious virus was detected after treatment when up to one-third of the APC unit was assayed, demonstrating a mean log10-reduction of >6.2. Potent inactivation of SARS-CoV therefore extends the capability of the INTERCEPT Blood System in inactivating a broad spectrum of human pathogens including recently emerging respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.